In this issue of Clinical Watch, we discuss new antipsychotic medication formulations to tailor the management of schizophrenia and suggest prior authorization criteria for a new treatment for Cushing’s disease. Lastly, we review claims data to identify the trends for use of Dupixent®.
For more information about a topic, please contact Janelle Sheen, Karen Powell or Mary-Beth Plum. Be sure to watch for future monthly updates. For more information about our solutions, please visit conduent.com/pharmacysolutions.
Conduent
Conduent Insights Hub
- All
- By Industry
-
By Service
- By Service
- Compliance Services
- Customer Experience
- Digital Payments
- Customer Experience Management Services
- Finance and Accounting
- Government Solutions
- Healthcare Solutions
- Human Resource Services
- Learning Services
- Legal Solutions
- Casualty Claims Solutions
- Mortgage Paperless Document Management
- Procurement Services
- By Type
